A Study to Evaluate the Efficacy and Safety of Tasimelteon in Treating Sleep Disturbances in Individuals With Autism Spectrum Disorder
Latest Information Update: 18 May 2022
At a glance
- Drugs Tasimelteon (Primary)
- Indications Autistic disorder
- Focus Registrational; Therapeutic Use
- Sponsors Vanda Pharmaceuticals
- 29 Apr 2022 Status changed from planning to recruiting.
- 17 Feb 2021 New trial record
- 10 Feb 2021 According to Vanda pharmaceuticals, this study is expected to be initiated in the first quarter of 2021.